1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Will Velphoro’s Convenience Advantage Be Enough In Crowded ESRD Field?

 
• By Sarah Karlin-Smith

With the field going generic and a new brand competitor with additional advantages on the way, Vifor Pharma is counting on lower pill burden to propel hyperphosphatemia drug Velphoro.

Vifor Pharma Ltd. is banking on the convenience of fewer pills per day to propel its newly approved hyperphosphatemia drug Velphoro (sucroferric oxyhydroxide) to success. But it’s unclear whether the dosing advantage will be enough to overcome soon-to-be generic competitors, a potential branded competitor with benefits beyond phosphate control and a changing reimbursement landscape.

FDA approved Velphoro, formerly known as PA21, Nov. 28 for the control of serum phosphorus levels in patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 
• By Bridget Silverman

Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.

Organ-On-A-Chip: Upcoming US FDA Guidance Could Help Flesh Out ‘Roadmap’

 
• By Michael McCaughan

The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.

Access Risks Loom For All Drugmakers With Fourth Circuit Mifepristone Decision

 
• By Sarah Karlin-Smith

The FDA law establishing REMS authority does not preempt a West Virginia law that would restrict mifepristone use in the state, an appeals court said, a decision that could have broader ramifications for the agency’s authority to ensure drug access.